Darden Restaurants, Inc. (NYSE:DRI) shows strong potential in the bio-tech marketplace. The company flaunts an impressive
48% Return on Equity, suggesting high quality performance. Notable entities like
Belpointe Asset Management, Cerity Partners, AGP Franklin LLC, and Crux Wealth Advisors have adjusted their positions in Darden's stock, reflecting the dynamic nature of the investment landscape. Despite insider stock sell-offs, Darden's stocks emerge leading the
S&P gainers, fueled to a large extent by the sales growth driven mainly by branches of
Olive Garden and
LongHorn Steakhouse.
Jim Cramer has backed Darden's earnings due to Olive Garden’s robustness. Analyst price targets gravitate around
$201.38, while others like Guggenheim and KeyBanc set the price targets higher. Notably, Darden outperformed
Q2 expectations and achieved a nearly
15% surge in shares. Although DRI missed Q1 revenue estimates, there was a significant
6.9% EPS growth amid major expansion. Ongoing partnerships, like Darden's recent collaboration with Uber, point towards a promising sales outlook.
Darden Restaurants Stocks DRI News Analytics from Wed, 30 Oct 2024 07:00:00 GMT to Sat, 19 Apr 2025 09:39:53 GMT -
Rating 8
- Innovation 4
- Information 7
- Rumor -3
